Sorafenib in the Treatment of Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Report of Four Cases.
10.4166/kjg.2015.65.4.246
- Author:
Young Mi HONG
1
;
Ki Tae YOON
;
Mong CHO
;
Dae Hwan KANG
;
Hyung Wook KIM
;
Cheol Woong CHOI
;
Su Bum PARK
;
Jeong HEO
;
Hyun Young WOO
;
Won LIM
Author Information
1. Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea. ktyoon@pusan.ac.kr
- Publication Type:Case Reports
- Keywords:
Hepatocellular carcinoma;
Liver transplantation;
Recurrence;
Sorafenib
- MeSH:
Antineoplastic Agents/*therapeutic use;
Carcinoma, Hepatocellular/diagnosis/*drug therapy;
Female;
Humans;
Liver Neoplasms/diagnosis/*drug therapy;
*Liver Transplantation;
Male;
Middle Aged;
Neoplasm Recurrence, Local;
Niacinamide/*analogs & derivatives/therapeutic use;
Phenylurea Compounds/*therapeutic use;
Positron-Emission Tomography;
Tomography, X-Ray Computed
- From:The Korean Journal of Gastroenterology
2015;65(4):246-251
- CountryRepublic of Korea
- Language:English
-
Abstract:
With an increasing number of patients with hepatocellular carcinoma (HCC) undergoing liver transplantation (LT), tumor recurrence remains the main limiting factor for long-term survival. Although sorafenib is available for advanced HCC, there is still a lack of data on the use of sorafenib for treatment of recurrent HCC after LT. Here, we report on four cases of the use of sorafenib for treatment of recurrent HCC after LT. The median time of recurrence from LT was 4 months (range, 1-16 months). Two of the four evaluated patients showed stable disease, which was the best response and the duration of stabilization was 11 months and 5 months, respectively. One patient also experienced stable disease and remained in stable disease without sorafenib therapy for 29 months and the total duration of stabilization was 38 months. The remaining patient showed partial response but stopped treatment due to radiological tumor progression during treatment. Although all cases were high risk group for recurrence such as above Milan criteria, vascular invasion and tumor biology, clinical outcomes showed some good results. Therefore, sorafenib may be an acceptable treatment option for recurrent HCC after LT.
